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ABSTRACT
Objective: To determine the proportion of youth suicides in New York City from 1999 to 2002 in which antidepressants
were detected at autopsy. Method: This is a medical examiner surveillance study of suicides in New York City among
those younger than 18 years of age. The outcome measure is serum toxicology for antidepressants. Results: From 1999
through 2002, there were 41 individuals younger than 18 years of age among residents of New York City who committed
suicide. Thirty-six (87.8%) had a serum toxicological analysis and an injury death interval of 3 days or less. There was one
(2.8%) suicide in which both buproprion and sertraline were detected at the time of autopsy. Antidepressants were not
detected in any of the other youth suicides. Conclusions: The detection of antidepressants at autopsy was quite rare in
youth suicides in New York City from 1999 to 2002. J. Am. Acad. Child Adolesc. Psychiatry, 2006;45(9):1054Y1058.
Key Words: antidepressant, selective serotonin reuptake inhibitors, suicide.
There has been concern recently about a link between
antidepressants and suicidal ideation and attempts. In
2003, the Medicines and Healthcare Products Regula-
tory Agency (MHRA) of the United Kingdom issued a
warning that with the exception of fluoxetine, the
benefits of antidepressant use in patients younger than
18 years of age do not outweigh the risks. This was
based on reanalyses of placebo-controlled, randomized
clinical trials (RCTs) for which a final report was
issued in December 2004 (Committee on Safety of
Medicines, 2004).
The U.S. Food and Drug Administration (FDA)
subsequently conducted meta-analyses of data from 25
RCTs of antidepressants for depression, anxiety, and
attention-deficit/hyperactivity disorder in children and
adolescents and presented those results to joint meetings
of the Psychopharmacologic Drugs Advisory Committee
and the Pediatric Advisory Committee (Hammad, 2004).
(Note: The February 2004 FDA Advisory meeting ex-
amined 24 RCTs, whereas the September 2004 meeting
also included the data from the Treatment for Adoles-
cents with Depression Study [March et al., 2004].) Only
four of those RCTs demonstrated antidepressant efficacy
on the primary outcome. Furthermore, in aggregate
across the RCTs, there was a statistically significant
twofold elevation in risk of suicide attempts or ideation
among subjects on active medication relative to those on
placebo. These findings are disquieting and suggest that
the risk/benefit ratio involved in use of antidepressants
among youths may be unacceptable. As a result, the FDA
issued a black box warning regarding the need to monitor
for worsening of clinical symptoms and suicide risk in
children, adolescents, and adults taking antidepressants
(U.S. Food and Drug Administration, 2004a).
The FDA warning was based on suicidal ideation
and suicide attempts among subjects in the pediatric
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antidepressant RCTs. There were no suicides in the
more than 4,800 subjects who participated in the 25
RCTs that were examined. In contrast, in a population-
based study, we examine in this article whether the
association between antidepressants and suicidality
extends beyond suicidal ideation and suicide attempts
and applies to the most adverse outcome in the range of
suicidal behavior, suicide deaths, as well. The objective
of this article is to report the proportion of youth
suicides in New York City who had antidepressants
detected at autopsy from 1999 to 2002.
METHOD
Study Sample
This is a medical examiner surveillance study of people younger
than 18 years of age who committed suicide in New York City.
The Office of New York City Chief Medical Examiner investigates
all deaths believed to be suicides, homicides, or accidents and
instances of death unattended by a physician. The circumstances
and environment of the fatality including evidence gathered at the
investigation of the death scene (e.g., notes), statements from
family and friends, the decedent_s psychiatric and other medical
history, and toxicological data all are used to determine the
manner of death and specifically to distinguish between a suicide
and an accident.
Our research group manually reviewed the medical files of each
suicide that was certified by the Chief Medical Examiner of New
York City from 1990 through 2002 with funding from the National
Institute of Drug Abuse (R01DA06534, Principal Investigator:
Kenneth Tardiff, M.D.). Elsewhere, we reported the results of
toxicologic analyses of a variety of psychotropic drugs in suicides
(Marzuk et al., 1995) and antidepressants in youth suicide from
1993 to 1998 (Leon et al., 2004). In this report, we included
suicides that occurred from 1999 to 2002 among New York City
residents younger than age 18 years. Inclusion criteria required that
victims had undergone systematic toxicological analysis for
antidepressant drugs. Furthermore, we recorded the injuryYdeath
interval for all cases. Based on the elimination half-life of the various
antidepressants (Baselt, 2002), which ranges from hours to several
days, we did not include toxicological results for those who survived
more than 3 days. We used this strategy to reduce the chance of
false-negative results. However, in this study, 36 of the 38 (94.7%)
youth suicides with toxicology available died within 26 hours of
their self-inflicted injury. Although antidepressants were not
detected in the one suicide who lived longer than 72 hours, it is
uncertain whether that individual had taken an antidepressant
before the suicidal injury.
Toxicology
Antidepressants and their principal metabolites were screened at
the Office of the Chief Medical Examiner of New York City by gas
chromatography using a nitrogen phosphorous detector. The
quantitation limit is 0.1 mg/L. All positive findings were confirmed
by gas chromatography-mass spectrometry.
Study Variables
Demographic characteristics, serum toxicology, and method of
suicide were examined. There was concern that some suicides would
be misclassified as accidents and the resulting estimate of the
presence of antidepressants would be biased. Therefore, toxicology
was also examined for all accidental deaths in those younger than age
18 years of age.
Data Analyses
The analyses that were used involve descriptive statistics. The
proportion of suicides and accidents with antidepressants detected
at autopsy is presented.
RESULTS
Suicides
Among New York City residents younger than age
18 years, there were 41 suicides from 1999 through
2002. Based on the New York City population ages
10Y17 years of 838,276 in 2000 (New York State
Department of Health, 2000), this amounts to an
annual rate of 1.22/100,000 compared to the U.S. rate
for that age group of 3.11/100,000 (National Center
for Injury Prevention and Control, 2005). Twenty-
eight (69.8%) of the suicides were males (Table 1).
There were more Hispanic Americans (n = 14, 34%)
and African Americans (n = 12; 29%) than whites
(n = 8; 19.5%), and this reflects the ethnic breakdown
for that age group in New York City. Decedents ranged
in age from 10 to 17 years (mean = 15.4, median = 16.0,
SD = 1.9). Three of the suicides were younger than 13
years of age.The most common methods of suicide were
hanging (n = 17; 41.5%), jump from heights (n = 8;
19.5%), and firearms (n = 5; 12.2%).
Results of toxicological analyses were available for 38
(92.7%) of the 41 suicides. Thirty-six (87.8%) of the
suicides had both toxicology and injury-death intervals of
3 days or less, and our examination of the presence of
antidepressants was limited to those subjects. Both
buproprion and sertraline were detected in one (2.8%)
of the suicides, a 16-year-old homeless African American
male who died of an intentional drug overdose.
Antidepressants were not detected in any other suicides.
Accidents
The Office of the Chief Medical Examiner of New
York City certified 269 residents of New York City
younger than age 18 years who died in accidents from
1999 through 2002. On average, those dying of accidents
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(mean = 9.0 years, median = 9.0, SD = 5.7) were younger
than the suicides. One hundred seventy-six (65.4%) were
males. Nearly 52% of these youths were younger than 10
years of age. One hundred twelve (42%) were African
American, 27 (28.6%) were Hispanic, and 55 (20.4%)
were white. Pedestrian fatalities were the most common
cause (n = 70; 26%). Toxicology was tested in 241 (90.3%)
of the accidental deaths and 213 (79.8%) had both
toxicology results available and injuryYdeath intervals of 3
days or less. Imipramine was detected in two (0.9%) of the
accidental deaths. Antidepressants were not detected in any
of the other accidental deaths.
DISCUSSION
This medical examiner surveillance study examined
serum toxicology for antidepressants among indi-
viduals who committed suicide and were younger than
18 years of age in New York City. Only one of those
suicides had antidepressants detected at the time of
autopsy. Antidepressants were detected in none of the
other suicides.
This finding concurs with those of our earlier study,
which found that antidepressants were detected in 4 of
54 (7.4%) youth suicides in New York City from 1993
to 1998 (Leon et al., 2004). On the surface, these results
may appear to be inconsistent with the results of the
FDA meta-analyses of 25 pediatric antidepressant
RCTs on which the antidepressant black box warning
is based. The analyses presented here, however, do not
have direct bearing on the question of whether there is
an association between antidepressants and non lethal
suicidal ideation or suicide attempts. Instead, we found
that antidepressants appeared to play little if any role in
suicides among children and adolescents in New York
City from 1999 to 2002. Similarly, none of the 4,800
study participants in the pediatric studies committed
suicide during the course of the RCTs. Instead, the
black box warning label is based on an increase in
suicidal ideation and suicide attempts among those
assigned to antidepressants relative to placebo. It is also
worth noting that six of those studies excluded subjects
with history of suicide attempts and most excluded
volunteers with active suicidality.
A study of suicides in Sweden from 1992 to 2000
found that antidepressants were detected in 7 of 52
(13.4%) suicides younger than 15 years of age and in 13
of 324 (4.0%) suicides 15 to 19 years of age (Isacsson
et al., 2005). Other types of studies, primarily in adults,
have examined the association between antidepressants
and suicidality. First, a report on a series of cases de-
scribed an association between fluoxetine and suicidality
(Teicher et al., 1990). Yet, subsequent observational
studies have not shown an elevated risk of suicidality in
those taking selective serotonin reuptake inhibitors
(Ham, 2003; Isacsson et al., 1996; Leon et al., 1999;
Martinez et al., 2005; Warshaw and Keller, 1996).
Kessler et al. (2005) found no change in rate of suicide
ideation and attempts during the past decade, a time
when antidepressant use increased in the United States.
Several ecological studies have found an inverse rela-
tionship between antidepressant sales and suicide rates
(Carlsten et al., 2001; Gibbons et al.,2005; Grunebaum
et al., 2004; Olfson et al., 2003), but they were unable to
determine whether each suicide had been treated with
antidepressants. In our study, we used medical examiner
TABLE 1
Description of Suicides Younger Than 18 Years of Age in
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certification of each suicide and toxicological analyses to
determine antidepressant exposure among the suicides.
One RCT specifically recruited suicidal adults and
demonstrated a protective effect of paroxetine (Verkes
et al., 1998), yet we are unaware of any such studies in
children or adolescents. Randomization would provide
a balance of demographic and clinical characteristics
between those who receive investigational and com-
parator treatments; however, randomized treatment
assignment with suicidal individuals introduces ethical
quandaries. Assignment would require careful choice
of comparison interventions and aggressive monitoring
of suicidality with comprehensive rescue provisions
detailed in the protocol. In fact, this strategy was suc-
cessfully implemented in an RCT for suicidal patients
with schizophrenia (Meltzer et al., 2003).
Limitations
There are several considerations relevant to the
interpretation of results of this study. First, we excluded
5 of the 41 suicides because toxicology was unavailable
or the injuryYdeath interval exceeded 72 hours. We
could not determine the presence or absence of
antidepressants for those cases. Our analyses did,
however, consider the possibility that we under
estimated antidepressant toxicology resulting from
misclassification of suicides as accidents. Antidepres-
sants were detected in only 2 of 213 youth victims of
fatal accidents. If there were misclassification of suicides
as accidents, then suicides without antidepressants in
toxicology would be more likely misclassified as acci-
dents because the medical examiner_s office uses all
information at its disposal to make a determination of
the cause of death. Therefore, if any misclassification
were present, then the overall proportion of suicides-
with positive antidepressant toxicology shown here
would likely be an overestimate, further strengthening
the inference being drawn here. Second, we recognize
that the detection level used in our study is such that we
could miss cases that had low antidepressant blood
concentration levels, below that of the screening
threshold set by the Office of New York City Chief
Medical Examiner. Third, we do not have information
about psychotherapeutic interventions or unfilled
prescriptions among the suicides. Finally, our findings
may be interpreted as evidence that the suicides that did
not have antidepressants detected at autopsy could have
been prevented by antidepressant treatment. However,
our post mortem study did not examine the protective
effect of antidepressants among youths in New York
City. Unfortunately, there are no precise estimates of
the number of youths who are treated with antidepres-
sants in New York City. Some studies (Gibbons et al.,
2005; Grunebaum et al., 2004; Olfson et al., 2003)
have examined prescription sales data, which are
proprietary and unavailable to us. Those published
data, however, do not correspond to the ages, calendar
years, or geographic area that we studied and therefore
do not provide estimates of antidepressant exposure in
youths in New York City.
Clinical Implications
This study found antidepressants in only 1 of 36
youth suicides in New York City from 1999 to 2002.
Although these results provide no evidence of a strong
link between antidepressants and suicide, they do not
rule out the possibility of suicidal thoughts or non lethal
suicide attempts among youths taking antidepressants.
Despite no demonstrable link at a population-based
level, we suggest that clinicians and parents continue to
carefully monitor the clinical status of youths who are
prescribed antidepressants (U.S. Food and Drug
Administration, 2004b).
Disclosure: Dr. Leon serves as a consultant to Cyberonics, Inc., and is on
two Data and Safety Monitoring Boards for Pfizer. The other authors
have no financial relationships to disclose.
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The Importance of Acknowledging Clinical Uncertainty in the Diagnosis of Epilepsy and Non-Epileptic Events R. Beach,
R. Reading
Background: Failure to recognise diagnostic uncertainty between the epilepsies and non-epileptic events may be a factor in high
rates of misdiagnosis. Aims: To explore the results of acknowledging diagnostic uncertainty in a cohort of children presenting with
paroxysmal events. Methods: Children (29 daysY16th birthday) with new presentations of paroxysmal disorders were ascertained
through outpatients, admissions, and accident and emergency over a two-year period in a district hospital with a catchment
population of 500,000. Cases were classified by diagnosis at entry and 6Y30 months later. A random selection of cases was
independently assessed. Results: A total of 684 cases were ascertained. Attacks were initially classified as febrile seizures (n = 212),
acute symptomatic epileptic seizures (n = 5), epilepsies (n = 83), unclassified (possible epilepsy) (n = 90), isolated epileptic seizures
(n = 51), and non-epileptic events (n = 243). Case review enabled reclassification of 61 of those initially unclassifiedV31 to an
epilepsy and 27 to non-epileptic events. In 29 the final diagnosis was never clarified. These were 23 cases with confusing or absent
histories and six with short lived seizure clusters. Prognosis for these 29 cases was good; 75% had been discharged. None were on
long term medication. The diagnosis in the 131 cases confirmed as epilepsy was stable. Independent review of a random sample
showed full concordance with one neurologist and 20% uncertainty with another. Conclusion: In addition to definite epilepsy or
non-epileptic events it is helpful to recognise a group of cases where the diagnosis is uncertainVunclassified paroxysmal events.
Reassessment of these cases enables accurate diagnosis and may prevent a hasty and incorrect diagnosis of epilepsy. Archives of
Disease in Childhood 2005;90:1219Y1222.
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